3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
10
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
3
enzalutamide
2
Testosterone
2
Itraconazole
2
Exercise
2
zanubrutinib
1
venetoclax
1
stenoparib
1
relugolix
1
olaparib
1
nilutamide
1
ibrutinib
1
histrelin
1
capivasertib
1
bicalutamide
1
apalutamide
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
acalabrutinib
1
abiraterone
1
Waiting Lists
1
Triptorelin Pamoate
1
Temozolomide
1
Surveys and Questionnaires
1
Radiosurgery
1
Prednisone
1
Pluvicto
1
PM 01183
1
Nutritional Status
1
Nivolumab
1
Methylprednisolone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
FED
×
Hydroxychloroquine
×
Clear all
NCT05842174
2026-04-16
TAQE
VA Office of Research and Development
Phase 1/2
Recruiting
93 enrolled